Terug

Tobii Dynavox AB (publ)

Datakwaliteit: 100%

Oversold

TDVXF

OTC Healthcare Medical - Instruments & Supplies

€ 8,40

▼ € 0,28 (-3,23%)

Marktkapitalisatie: 886,64M

Dagbereik

€ 8,40 € 9,00

52-Weeksbereik

€ 5,00 € 13,55

Volume

700

50D / 200D Gem.

€ 9,74 / € 11,06

Vorige Slotkoers

€ 8,68

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek	Aandeel	Sector Mediaan
P/E	5,3	0,2
P/B	1,5	3,0
ROE %	31,4	3,6
Net Margin %	6,7	3,8
Rev Growth 5Y %	29,7	9,9
D/E	1,8	0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2029	€ 7,29 € 6,59 – € 8,74	4,27B	1
FY2028	€ 5,76 € 5,20 – € 6,89	3,85B	1
FY2027	€ 4,55 € 4,12 – € 5,45	3,34B	1

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2026-02-05	€ 0,77	€ 0,08	-90,0%
2025-10-23	€ 0,06	€ 0,05	-13,0%
2025-07-18	€ 0,03	€ 0,03	-4,4%
2025-04-25	€ 0,02	€ 0,02	+8,4%
2025-02-05	€ 0,05	€ 0,05	-7,6%
2024-10-23	€ 0,05	€ 0,04	-14,3%
2024-07-18	€ 0,03	€ 0,03	+24,6%
2024-04-23	€ 0,02	€ 0,01	-59,2%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 29,72% annually over 5 years — strong growth

ROE of 31,41% indicates high profitability

Negative free cash flow of -8,00M

P/E of 5,34 — trading at a low valuation

Revenue growth is decelerating — 1Y growth trails 5Y average by 4,62%

Capital efficient — spends only 8,31% of revenue on capex

Groei

Revenue Growth (5Y)

29,72%

Revenue (1Y)25,10%

Earnings (1Y)13,70%

FCF Growth (3Y)N/A

Kwaliteit

Return on Equity

31,41%

ROIC11,16%

Net Margin6,73%

Op. Margin10,30%

Veiligheid

Debt / Equity

1,83

Current Ratio1,57

Interest Coverage5,42

Waardering

P/E Ratio

5,34

Forward P/E2,65

P/B Ratio1,47

EV/EBITDA7,07

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	25,10%	Revenue Growth (3Y)	23,66%
Earnings Growth (1Y)	13,70%	Earnings Growth (3Y)	26,28%
Revenue Growth (5Y)	29,72%	Earnings Growth (5Y)	53,63%
Profitability
Revenue (TTM)	2,47B	Net Income (TTM)	166,00M
ROE	31,41%	ROA	6,71%
Gross Margin	68,42%	Operating Margin	10,30%
Net Margin	6,73%	Free Cash Flow (TTM)	-8,00M
ROIC	11,16%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	1,83	Current Ratio	1,57
Interest Coverage	5,42
Dividends
Dividend Yield	0,00%	Payout Ratio	0,00%
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	5,34	Forward P/E	2,65
P/B Ratio	1,47	P/S Ratio	0,36
PEG Ratio	4,96	Forward PEG	N/A
EV/EBITDA	7,07	Fwd EV/EBITDA	1,95
Forward P/S	0,31	Fwd Earnings Yield	37,74%
FCF Yield	-0,90%
Market Cap	886,64M	Enterprise Value	1,80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	2,47B	1,97B	1,61B	1,22B	871,20M
Net Income	166,00M	146,00M	104,10M	48,60M	29,80M
EPS (Diluted)	1,56	1,37	0,98	0,46	0,30
Gross Profit	1,69B	1,36B	1,09B	787,80M	570,20M
Operating Income	254,00M	228,50M	154,80M	82,30M	60,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	2,47B	2,00B	1,69B	1,32B	1,15B
Total Liabilities	1,87B	1,54B	1,39B	1,11B	1,01B
Shareholders' Equity	603,00M	454,00M	297,80M	210,60M	139,50M
Total Debt	1,10B	791,00M	773,30M	628,30M	606,70M
Cash & Equivalents	195,00M	133,00M	161,10M	106,80M	197,30M
Current Assets	1,08B	813,30M	633,40M	487,60M	446,00M
Current Liabilities	686,00M	630,00M	538,80M	425,00M	305,90M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)

Rank = position among all matches

Growth Price/Sales Ratio Focus (Ken Fisher)

#112 of 619

Recente Activiteit

Uitgestapt Contrarian Investing (David Dreman)

Mar 26, 2026

Ingestapt Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Ingestapt Contrarian Investing (David Dreman)

Mar 24, 2026